Autologous stem cell transplantation in multiple myeloma is not dead but alive and well

Bibliography

• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7
   PubMed Web of Science ®Google Scholar
• Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. Am Soc Clin Oncol Educ Book 2014;199-203
   PubMedGoogle Scholar
• Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
   PubMed Web of Science ®Google Scholar
• Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755-9
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-33
   PubMed Web of Science ®Google Scholar
• Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-36
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589-96
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371(10):895-905
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28(30):4621-9
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial. J Clin Oncol (2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition)). 2008. 26: 15S(20 Suppl): 8505
   Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD. Blood (ASH Annual Meeting Abstracts) 2009;114:abstract 351
   Google Scholar
• Passweg JR, Baldomero H, Peters C, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49(6):744-50
   PubMed Web of Science ®Google Scholar
• Costa LJ, Zhang MJ, Zhong X, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013;19(11):1615-24
   PubMed Web of Science ®Google Scholar
• Martino M, Montanari M, Ferrara F, et al. Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. Biol Blood Marrow Transplant 2014;20(7):1026-32
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology Am Soc Hematol Educ Program 2012;2012:354-61
   PubMedGoogle Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-85
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013;31(26):3279-87
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102(5):1115-23
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86(1):57-65
   PubMed Web of Science ®Google Scholar
• Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687-91
   PubMed Web of Science ®Google Scholar
• Mohty M, Ho AD. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp Hematol 2011;39(7):723-9
   PubMed Web of Science ®Google Scholar
• Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009;43(3):181-95
   PubMed Web of Science ®Google Scholar
• Lemoli RM. New strategies for stem cell mobilization. Mediterr J Hematol Infect Dis 2012;4(1):e2012066
   PubMedGoogle Scholar
• Tageja N, et al. Carfilzomib and bortezomib containing regimens yield high rates of MRD negative autologous hematopoietic progenitor cell (HPC) grafts in multiple myeloma (MM) and high risk smoldering myeloma (SMM). Blood [Annual Meeting Abstracts]. 2013. 122(21):Abstract 2030
   Google Scholar
• Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001;27:837-42
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349(26):2495-502
   PubMed Web of Science ®Google Scholar
• Harousseau JL. Hematopoietic stem cell transplantation in multiple myeloma. J Natl Compr Canc Netw 2009;7:961-70
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. J Clin Oncol 2007;25(17):2434-41
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119(4):940-8
   PubMed Web of Science ®Google Scholar
• Naumann-Winter F, Greb A, Borchmann P, et al. First-line tandem high dose chemotherapy and autologous stem cell transplantation versus single high-dosechemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlledstudies. Cochrane Database Syst Rev 2012;10:CD004626
   PubMedGoogle Scholar
• Atanackovic D, Schilling G. Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol 2013;163(5):565-72
   PubMed Web of Science ®Google Scholar
• Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37
   PubMed Web of Science ®Google Scholar
• McCarthy PL. Where are we going with autologous transplantation for multiple myeloma? Biol Blood Marrow Transplant 2013;19(11):1532-3
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014;15:333-42
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Gregory WM, Davies FE, et al. National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012;119(1):7-15
   PubMed Web of Science ®Google Scholar